Wilms' tumor 1 protein and estrogen receptor beta expression are associated with poor outcomes in uterine carcinosarcoma

Annals of Surgical Oncology

Volumn 20, Issue 7, 2013, Pages 2373-2379

  Guntupalli, Saketh R ^a   Cao, Dengfeng ^b,c   Shroff, Rupal ^d   Gao, Feng ^c   Menias, Christine ^e   Stewart Massad, L ^c   Powell, Matthew A ^c   Mutch, David G ^c   Thaker, Premal H ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^c Washington University in St Louis School of Medicine   (United States)

^d INDIANA UNIVERSITY   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ESTROGEN RECEPTOR BETA; IFOSFAMIDE; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; WILMS TUMOR 1 PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MYOMETRIUM; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCORING SYSTEM; TUMOR INVASION; UTERUS CARCINOMA; UTERUS SARCOMA;

AGED; CARCINOSARCOMA; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; HYSTERECTOMY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; UTERINE NEOPLASMS; WT1 PROTEINS;

EID: 84878859042     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2838-9     Document Type: Article

References (28)

1. Silverberg SG, Major FJ, Blessing JA, Fetter B, Askin FB, Liao SY, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol. 1990;9(1):1-19. (Pubitemid 20067452)
2. Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Biol. 2004;58(3):786-96. (Pubitemid 38221136)
3. Nemani D, Mitra N, Guo M, Lin L. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol. 2008;111(1):82-8.
4. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol. 2004;93(1):204-8. (Pubitemid 38429571)
5. Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007;107(2):177-85. (Pubitemid 47575740)
6. Pisani A BD, Chen D, et al. HER-2/neu, p53, and DNA analysis as prognosticators for survival in endometrial carcinoma. Obstet Gynecol. 1995;85:729.
7. Hutchings Y, Osada T, Woo CY, Clay TM, Lyerly HK, Morse MA. Immunotherapeutic targeting of Wilms' tumor protein. Curr Opin Mol Ther. 2007;9(1):62-9. (Pubitemid 46438450)
8. Oji Y, Nakamori S, Fujikawa M, Nakatsuka S, Yokota A, Tatsumi N, et al. Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci. 2004;95(7):583-7. (Pubitemid 39089639)
9. Dohi S, Ohno S, Ohno Y, Soma G, Kyo S, Inoue M. Correlation between WT1 expression and cell proliferation in endometrial cancer. Anticancer Res. 2009;29(11):4887-91.
10. Franko A, Magliocco AM, Duan Q, Duggan MA. WT1 immunoprofiling and comparison of malignant Mullerian mixed tumors of the female genital tract. Int J Gynecol Pathol. 2010;29(5):452-8.
11. Coosemans A, Moerman P, Verbist G, Maes W, Neven P, Vergote I, et al. Wilms' tumor gene 1 (WT1) in endometrial carcinoma. Gynecol Oncol. 2008;111(3):502-8.
12. Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, Leetanaporn R, Geater A. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study. BMC Cancer. 2006;6:90. (Pubitemid 43885028)
13. Ioffe YJ, Li AJ, Walsh CS, Karlan BY, Leuchter R, Forscher C, et al. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecol Oncol. 2009;115(3):466-71.
14. Huang GS, Gunter MJ, Arend RC, Li M, Arias-Pulido H, Prossnitz ER, et al. Co-expression of GPR30 and ERbeta and their association with disease progression in uterine carcinosarcoma. Am J Obstet Gynecol. 2010;203(3):242, e1-5.
15. Guntupalli SR, Zighelboim I, Kizer NT, Zhang Q, Powell MA, Thaker PH, et al. Lymphovascular space invasion is an independent risk factor for nodal disease and poor outcomes in endometrioid endometrial cancer. Gynecol Oncol. 2012;124(1):31-5.
16. Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res. 2004;10(15):5145-50. (Pubitemid 39099789)
17. Sutton G, Kauderer J, Carson LF, Lentz SS, Whitney CW, Gallion H. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;96(3):630-4. (Pubitemid 40255480)
18. Chi DS, Mychalczak B, Saigo PE, Rescigno J, Brown CL. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol. 1997;65(3):493-8. (Pubitemid 27255994)
19. de Jong RA, Nijman HW, Wijbrandi TF, Reyners AK, Boezen HM, Hollema H. (2011) Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component. Mod Pathol. 24(10):1368-79.
20. Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, et al. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-βeta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol. 2010;117(2):248-54.
21. Cilloni D, Messa F, Gottardi E, Fava M, Arruga F, Defilippi I, et al. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer. 2004;101(5):979-88. (Pubitemid 39100432)
22. ®. 2011. http://www.nccn.org/professionals/physician-gls/pdf/uterine.pdf. Accessed Jan 2012.
23. Acs G, Pasha T, Zhang PJ. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol. 2004;23(2):110-8. (Pubitemid 38391769)
24. Coosemans A, Van Calster B, Verbist G, Moerman P, Vergote I, Van Gool SW, et al. Wilms tumor gene 1 (WT1) is a prognostic marker in high-grade uterine sarcoma. Int J Gynecol Cancer. 2011;21(2):302-8.
25. Coosemans A, Nik SA, Caluwaerts S, Lambin S, Verbist G, Van Bree R, et al. Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas. Eur J Cancer. 2007;43(10):1630-7. (Pubitemid 46891806)
26. Ohno S, Kyo S, Myojo S, Dohi S, Ishizaki J, Miyamoto K, et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Res. 2009;29(11):4779-84.
27. Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 2010;116(2):171-9.
28. Van Driessche A, Berneman ZN, Van Tendeloo VF. (2012) Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist. 17(2):250-9.